Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06641908 · ClinicalTrials.gov registry record · Phase 1

Anti-GD2 ADC M3554 in Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by EMD Serono Research & Development Institute.

Recruiting
Registry status
Phase 1
Development phase
52
Enrollment target
11
Study locations

NCT06641908 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by EMD Serono Research & Development Institute. The registered enrollment target is 52 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (73% lower). The trial reports 11 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06641908, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by EMD Serono Research & Development Institute.

RECRUITING
Registry status
Phase 1
Development phase
52 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG M3554

Study Locations (11)

Other

  • UZ Leuven - Leuven
  • Institut Bergonié - Service d'Oncologie Médicale - Bordeaux
  • Centre Oscar Lambret - cancerologie generale - Lille
  • Centre Leon Berard - Service d'Oncologie Medicale - Lyon
  • Centre Antoine Lacassagne - Service d'Hématologie Oncologie - Nice
  • National Cancer Center Hospital - Chūōku
  • Universitaetsspital Zuerich - Klinik fuer Neurologie - Zurich

Massachusetts

  • Dana-Farber Cancer Institute - Boston

New York

  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc - New York

Texas

  • The University of Texas MD Anderson Cancer Center - Houston

Surrey

  • Royal Marsden Hospital-Sutton - Dept of Oncology (Surrey) - Sutton

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2024-11-08
Est. Completion 2027-04-16
Phase Phase 1

Sponsor

EMD Serono Research & Development Institute

81 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06641908

The ClinicalTrials.gov registry entry for NCT06641908 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (73% lower). The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which M3554 is the first listed.

NCT06641908 reports 11 study locations spanning 5 distinct geographic areas - top geographies include Other, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT06641908 about?

NCT06641908 is a clinical study titled "Anti-GD2 ADC M3554 in Advanced Solid Tumors". The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months

What is the current status of trial NCT06641908?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2024-11-08. Estimated completion is 2027-04-16.

What conditions does trial NCT06641908 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06641908?

The interventions under investigation include: M3554 (DRUG).

Who is sponsoring clinical trial NCT06641908?

This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06641908 being conducted?

This trial has 11 study locations across Massachusetts, New York, Texas, Surrey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.